PUVA vs Tofacitinib for Generalized Vitiligo
Part of Skin clinical trials.
This study compares two treatments for widespread vitiligo: a light therapy combined with a medicine called psoralen (PUVA) versus a pill called tofacitinib. It will help find which option works better and is safer for people with stable, extensive vitiligo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have generalized vitiligo (white patches on more than 10% of your body).
- Your vitiligo has been stable (no new patches or changes) for at least 3 months.
- You are not allergic or sensitive to psoralen or tofacitinib.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with active generalized vitiligo covering more than 5% of their body (not counting hands and feet). It also looks at a protein in the blood called s100B to see how it relates to the condition and treatment response.
This study compares two treatments for vitiligo: narrowband UVB light therapy combined with either tacrolimus ointment or calcipotriol ointment. It aims to see which combination works better and is safer for people with stable, limited vitiligo.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This study compares two systemic medications—methotrexate (a traditional immunosuppressant) and tofacitinib (a newer targeted therapy)—to see which works better for moderate-to-severe plaque psoriasis that hasn't responded well to creams or ointments.
This trial compares two medications, tofacitinib and methotrexate, to see which works better for severe hair loss caused by alopecia areata. If you have severe alopecia areata (total or universal hair loss), this study may offer a chance to try a new treatment option.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
Hear when a new Vitiligo, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.